Hetero Drugs Sustainability Profile
Hetero Drugs Limited, commonly referred to as Hetero, is a prominent player in the global pharmaceutical industry, headquartered in Hyderabad, India. Established in 1993, the company has made significant strides in the development and manufacturing of a diverse range of generic and branded medications, particularly in the areas of anti-retrovirals, oncology, and cardiovascular treatments. With a strong presence in over 120 countries, Hetero is recognised for its commitment to quality and affordability, making essential medicines accessible to patients worldwide. The company’s extensive portfolio includes over 200 products, distinguished by their rigorous quality standards and innovative formulations. Hetero's dedication to research and development has positioned it as a leader in the pharmaceutical sector, contributing to its reputation for excellence and reliability in healthcare solutions.
DitchCarbon Score
How does Hetero Drugs's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hetero Drugs's score of 27 is lower than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hetero Drugs's reported carbon emissions
In 2024, Hetero Drugs reported total greenhouse gas emissions of approximately 405.7 million kg CO2e, comprising 196.1 million kg CO2e from Scope 1 and 209.6 million kg CO2e from Scope 2 emissions. This reflects a slight decrease from the previous year's total of approximately 412.5 million kg CO2e, which included 213.3 million kg CO2e from Scope 1 and 199.1 million kg CO2e from Scope 2. Hetero Drugs has not disclosed any Scope 3 emissions data, and there are currently no specific reduction targets or climate pledges outlined in their sustainability reports. The company has not cascaded any emissions data from a parent organization, indicating that all reported figures are derived directly from Hetero Drugs Limited. The company continues to monitor its emissions and is committed to improving its sustainability practices, although specific initiatives or targets have not been detailed in the available data.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 222,286,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 117,362,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - |
How Carbon Intensive is Hetero Drugs's Industry?
How Carbon Intensive is Hetero Drugs's Location?
Hetero Drugs's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Hetero Drugs has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.